Edodekin alfa

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameEdodekin alfa
Drug Alias NameCLMFNKSFRecombinant human interleukin-12rHuIL-12rhIL-12 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-12 receptor stimulants
TargetsInterleukin-12 receptor
Therapy Area/IndicationsSolid tumoursGraft vs Host DiseaseAsthma +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesWistar InstituteValeantF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesWistar InstituteF. Hoffmann-La Roche LtdBausch Health Companies Inc +[4] 
Active IndicationsSquamous Cell Carcinoma of Head and NeckCarcinoma, Squamous Cell
Inactive IndicationsSolid tumoursGraft vs Host DiseaseAsthma +[19] 

Other Information

ATC CodeN/A
Related LinksN/A